40 results about "Mucosal inflammation" patented technology

The present invention includes compositions and methods for the treatment and prevention of oral mucosal disorders and for promotion of bone health. In particular, the present invention describes new therapeutic and preventative uses for 3,3′-diindolylmethane (DIM), or a DIM-related indole, alone or in combination with anti-inflammatory agents and / or antibacterial agents, to treat oral mucosal disorders and promote bone health. The compositions of the invention are used to prevent and reverse oral mucosal disorders and bone loss (osteopenia and osteoporosis) associated with aging and chronic inflammation. Oral mucosal disorders include Periodontitis, gingivitis and related oral mucosal inflammation. Formulations of the compositions of the invention include capsules, tablets, toothpastes, oral gels, mouthwashes, mouth rinses, lozenges, chewing gum, dental floss, and dental topical formulations, and fortified foods.

A nasal spray composition for treating mucosal inflammation associated with rhinitis, sinusitis, or both can include a decongestant and at least one therapeutic agent. The therapeutic agent is selected from the group consisting of an anti-inflammatory agent and an anti-histamine agent. The nasal spray composition is non-habituating and is administered intranasally to a subject in need thereof.

The invention relates to the compounds of formula I, formula II, formula III, formula IV and formula V or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV or formula V and methods for the treatment of inflammation and pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of pain, oral mucosal inflammatory or oral infectious diseases.

The invention relates to a mussel adhesive protein (MAP) and an application thereof in inhibiting catarrh, and specifically, to applications of a MAP or a product thereof in oral mucositis, rhinitis, otitis media, pharyngitis, laryngitis, bronchitis, esophagitis, gastritis, enteritis, cervicitis, endomyometritis, inflammation resulting from inhalation injury, and oral cavity cancer, nasopharyngeal cancer, carcinoma of middle ear, conjunctival cancer, laryngeal cancer, lung cancer, esophageal cancer, stomach cancer, bowel cancer, cervical cancer, endometrial cancer, and other cancers resulting from the inflammation. The MAP can inhibit symptoms such as flush, fever, swell, and pain owing to catarrh, facilitating healing, relieving itch and pain, and having broad applications in the fields of medicines, cosmetics, medical products, disinfection products, healthcare products, foods, and household goods.

The invention provides for a therapeutic causing contraction of a mucosal tissue whereby various diseases relating to mucosal tissues can be easily, safely and treated with minimal invasiveness, a method of treating various diseases relating to mucosal tissues with the use of the therapeutic causing contraction of a mucosal tissue, and an injector and a therapeutic set usable in the treatment method. The invention also encompasses a therapeutic causing contraction of nasal mucosal tissue containing ethanol as the active ingredient preferably together with a steroid and / or an antihistaminic agent; a method of treating diseases with mucosal inflammation using the above therapeutic causing contraction of a mucosal tissue, and an injector and a therapeutic set usable in the treatment method.

The invention relates to wine, in particular to wine added with tea tree essential oil. The amount of the tea tree essential oil added to the wine is from one hundred thousandth to three ten thousandths of wine volume. The wine with tea tree essential oil can help an immune system of a human body to resist infectious diseases and has certain curative effect on influenza, lip herpes and mucosal inflammation, can be also used for treating gland pyrexia and gingival inflammation, can alleviate the secretion of adrenal gland sebum, soothe the gloom and irritable mood, inspire spirits, improve sleeping, relieve stress, adjust the hormone level, increase sexual desire, improve the menstrual disorder, improve the decreased sexual desire and the sexlessness amazingly, enhance the immunity of an organism, improve and boost the function of a urinary system, nourish kidney and promote expelling of toxin and metabolism and has the function of diuresis and the excellent improvement effect on aging skins, dry skins or sensitive skins.

The invention relates to a mussel adhesive protein (MAP) and an application thereof in inhibiting catarrh, and specifically, to applications of a MAP or a product thereof in oral mucositis, rhinitis, otitis media, pharyngitis, laryngitis, bronchitis, esophagitis, gastritis, enteritis, cervicitis, endomyometritis, inflammation resulting from inhalation injury, and oral cavity cancer, nasopharyngeal cancer, carcinoma of middle ear, conjunctival cancer, laryngeal cancer, lung cancer, esophageal cancer, stomach cancer, bowel cancer, cervical cancer, endometrial cancer, and other cancers resulting from the inflammation. The MAP can inhibit symptoms such as flush, fever, swell, and pain owing to catarrh, facilitating healing, relieving itch and pain, and having broad applications in the fields of medicines, cosmetics, medical products, disinfection products, healthcare products, foods, and household goods.

The invention discloses a coupling matter formed by chemical modification of polyethylene glycol of a deletion-recombination human keratinocyte growth factor I type. The coupling matter is characterized in that covalent chemical coupling is performed on activated polyethylene glycol molecules with the molecular weight being 5K to 40K and free sulfhydryl in 79-site cysteine of the deletion-recombination human keratinocyte growth factor I type (delta 23KGF-I) with the deletion of 23-site amino acid at the N terminal, and then column chromatography purification is performed to obtain the pegylation deletion-recombination human keratinocyte growth factor I type. The coupling matter retains the biological effects of human keratinocyte growth factors, changes the internal metabolic dynamics characteristic of the factors and has values of prevention and therapy on digestive tract mucosa damage or ulcerative mucosal inflammation caused by radiotherapy and chemotherapy as well as on acute chemical liver damage.

The invention discloses rapid antibacterial gynecological gel, which comprises the following components in parts by weight: 4-6 parts of helichrysum, 5-8 parts of L-ascorbyl 6-palmitate, 6-8 parts oflonicera japonica, 1-3 parts of purslane, 6-10 parts of fructus cnidii, 2-5 parts of blackend swallowwort root, 4-6 parts of fructus kochiae, 6-10 parts of pomegranate extract, 2-6 parts of centella,6-10 parts of menthol, 15-20 parts of policresulen, 1-2 parts of a cationic antimicrobial agent, 30-50 parts of hydroxymethyl cellulose, 50-100 parts of glycerin and 50-100 parts of propylene glycol.The rapid antibacterial gynecological gel disclosed by the invention has an antibacterial effect, and can prevent breeding of harmful bacteria; the product is weakly acidic, the acid-base balance in the vagina is maintained, and the health state of private parts of women is maintained; and the effective microbial community can be effectively protected, the ability of engulfing bacteria and virusesby in-vivo leukocyte can be enhanced, the resisting ability to the bacteria and viruses is enhanced, aching feeling of the human body caused by various reasons is alleviated, harmful infection is prevented, the wounds are rapidly healed, the detoxification ability is improved, and the antibacterial rate of vulvar mucosal inflammation caused by secondary infection of the female genital tract can reach 90%.

The invention provides an orthodontic micro-implant anchorage nail which comprises an anchorage nail head, an anchorage nail neck and an anchorage nail thread part, wherein the anchorage nail head is formed by a solid cuboid which is 2mm thick; a cutting angle, near the neck, of the cuboid is lost; the design is adapted to the inclination degree of the surface of a gingival mucosa surface of the implant part; the geometric profile on the surface of the implant is prevented from oppressing gingival to cause mucosa inflammation; cleaning of the periphery of the anchorage nail is facilitated. The upper part of the anchorage nail head is narrowed to form a ligation head; the transgingival part of the anchorage nail neck is smooth in appearance and is 2mm long; an antibacterial biological coating is formed in the surface; bacterial plaques are prevented from being formed; the anchorage nail thread part comprises a cortical bone segment and a cancellous bone segment; and the cortical bone segment is in a fine thread structure which is 2mm long; and the other cancellous bon segment is in a thin thread structure. The orthodontic micro-implant anchorage nail has the structure characteristics that the stability of the anchorage nail is facilitated; and the expulsion rate of the anchorage nail is reduced.

The invention, relating to a novel application of dendrobium candidum, aims at providing an application of dendrobium candidum in preparing medicines for treating immune chronic gastritis. The invention discloses the application of dendrobium candidum in preparing medicines for treating immune chronic gastritis, and a preparation method of medicines for treating immune chronic gastritis based on dendrobium candidum. The invention provides a novel means for treating immune chronic gastritis. According to the invention, the effects of mitigating body weight loss, mitigating gastric mucosal inflammation, hyperaemia, hemorrhage and erosion, decreasing mortality ratio, and mitigating atrophy of gastric mucous are achieved. The dendrobium candidum wall.ex lindl drop(DCWD) disclosed herein has mild formula, is suitable for conditioning and rehabilitation of spleen and stomach diseases with excess and deficiency syndromes due to spleen-stomach deficiency or sthenia symptoms caused by asthenia. The treatment of Chinese medicines has good safety. The Chinese medicines can be taken for a long time, and has the combined actions of consolidating curative effect, preventing a recurrence and adjusting the whole body.

Disclosed herein are methods for treating mucositis (e.g., Alternaria-activated mucositis) that involves the direct mucoadministration of an active agent that is antifungal and antibacterial in an amount and for a duration effective to treat mucositis.

The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV and formula V and the methods for the treatment of xerostomia may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral mucosal inflammatory, dry mouth or oral dry mouth mediated infectious diseases.

The invention discloses a degradable 3D printing nasal sinus stent loaded with drugs and a preparation method thereof. The stent can be implanted after sinus dilation to prevent nasal adhesion, and the stent can be slowly degraded along with the release of drugs, which can affect the lesion location. Continue treatment with medication. The invention uses degradable PLA material as raw material, adopts 3D printing technology, and fuses the drug load into the process of forming the 3D printing material. The drug release cycle of the stent is consistent with the material degradation cycle, which can meet the time requirement for wound healing after sinus dilation surgery, and can effectively solve the problem of short drug release time for general drug-coated stents. The degradable drug support for the nasal cavity and paranasal sinuses obtained by the invention can reduce mucosal inflammation and edema, promote mucosal healing, reduce scar formation, and eliminate postoperative adhesions, thereby alleviating the pain of patients and reducing the economic burden of patients.

The invention discloses an oral antibacterial composition containing essential oil and a preparation method of the oral antibacterial composition. The oral antibacterial composition takes disinfectant polyhexamethylene biguanide, chlorhexidine gluconate and the like and an essential oil composition of lavender essential oil, tea tree essential oil and garlic essential oil as main effective ingredients, has a good antibacterial effect, can effectively inhibit periodontitis and relieve pain, can resist inflammation and refresh breath, and has a good taste. The product has good stability, the mouthwash is convenient to use at any time, and the gel can quickly eliminate oral mucosa inflammation at a fixed point and is convenient to use.

The invention discloses an implant for improving the sealing performance of soft tissue around the implant. The implant comprises a body part and a base foundation or a neck part, wherein the base foundation is connected with the body part through a screw; the neck part is integrally connected with the body part; the upper part of the body part matches with the bottom of the base foundation to form a shoulder foundation of 0.2-0.7mm wide; a first micro pore zone of 3-5mm wide is arranged on the implant; first micro pores which are uniformly distributed are formed in the first micro pore zone;the size of the first micro pores is 1-3 micrometers; the surface of an area above the first micro pore zone is a smooth surface; and the first micro pore zone is positioned on the surface of the basefoundation or the neck part above the top of the body part. The implant emphasizes on creativeness of the sealing performance of a gum threading part of the implant, the adhesiveness of soft tissue to the implant is improved, mucosal inflammation around the implant and peri-implantitis can be reduced, and the long-term success rate of implanting can be increased.

The invention discloses toner with a skin mucosal inflammation treatment effect and a preparation method thereof. The toner is prepared from the following raw materials in parts by weight: 0.06 to 0.15 part of adrenaline, 5.2 to 7.5 parts of rape flower, 4 to 8 parts of butylene glycol, 0.02 to 0.08 part of sodium hyaluronate, 0.65 to 1.24 parts of squalane, 3.3 to 4.6 parts of rosemary, 0.8 to 1.22 parts of anthocyanin, 0.5 to 2.2 parts of polyvinylpyrrolidone, 56 to 75 parts of water and 2.5 to 4 parts of carbomer. The different raw materials are treated through different preparation technologies to obtain different products; the different products are mixed; under the cooperative effect of all the products, a prepared finished product has the effects of keeping faces fresh and non-sticky, moisturizing, hydrating, and enabling skin to be moisturized and smooth and have elasticity, and also can be used for inhibiting inflammatory response of skin mucosal inflammation, so that the symptoms including pruritus, erythra and the like are alleviated.

The invention provides anorectal gel which has the effects of moisturizing, relieving itching, cooling, stopping bleeding, diminishing inflammation, easing pain, promoting healing of mucosal inflammation, regulating intestinal functions and improving human immunity, and provides a preparation method of the anorectal gel. The anorectal gel comprises the following components: 0.05 to 0.5 part by weight of hyaluronic acid or sodium salt thereof, 5 to 20 parts by weight of pearl powder, 5 to 10 parts by weight of freeze-dried powder of live bifidobacterium, 0.05 to 2 parts by weight of sodium azulene sulfonate, 0.01 to 2 parts by weight of borneol and 68.5 to 90 parts by weight of water. The preparation method of the gel comprises the following steps: dissolving the sodium azulene sulfonate insterile water, sequentially adding the freeze-dried powder of bifidobacterium, pearl powder and borneol, stirring the mixture uniformly, adding hyaluronic acid, and carrying out uniform stirring to obtain the anorectal gel. The anorectal gel prepared by the invention has the functions of moisturizing, relieving itching, cooling, stopping bleeding, diminishing inflammation, easing pain, promotinghealing of anorectal mucosa inflammation, regulating intestinal functions and improving human immunity, and can be used for rapidly relieving pain brought by anorectal diseases to patients, and promoting rapid healing of anorectal inflammation, micro-injury and wounds.

The invention provides a composition of an externally applied drug for treating intraluminal mucosal inflammation, the externally applied drug, a preparation method and application of the externally applied drug, and belongs to the technical field of drugs for intraluminal mucosal inflammation. The composition of the externally applied drug for treating intraluminal mucosal inflammation comprisesa first ozone gel which comprises ozone, vegetable oil or / and deep sea fish oil, and the concentration of ozone in the first ozone gel is 100 to 130 g / L. The externally applied drug for treating intraluminal mucosal inflammation is prepared from the composition, and the preparation method comprises the step of introducing ozone into the vegetable oil or / and deep sea fish oil to obtain the first ozone gel with the concentration of ozone of 100 to 130 g / L. The externally applied drug for treating intraluminal mucosal inflammation prepared from the composition with the preparation method can effectively treat intraluminal mucosal inflammation, such as, gynecological inflammation, such as vaginitis, cervicitis and intrauterine inflammation, and can also used for treating rhinitis, stomatitis,intestinal inflammation and other inflammation, and the externally applied drug is good in treatment effect and takes effect quickly.

Provided is a positioning immediate-release bioadhesive and relates to a medical device for preventing or / and treating diabetes, obesity, alcoholism, gastric and intestinal mucosal inflammation or / and ulcers and the like. The positioning immediate-release bioadhesive is prepared by preparing a biocompatible bioadhesive material into micro-particles, externally adding an immediate-release disintegrant, tabletting and then performing enteric or gastric coating; or performing enteric or gastric coating on the micro-particles; or filling into enteric-coated or gastric-coated hollow capsules; or directly tabletting the bioadhesive material, the immediate-release disintegrant and other additional agents and then performing enteric or gastric coating. After the positioning immediate-release bioadhesive is taken, the positioning immediate-release bioadhesive can realize positioning and immediate release, rapidly adhere to and cover the upper segment of duodenum and jejunum or / and gastric mucosa and weaken the absorption of the upper segment of duodenum and jejunum or / and stomach. The positioning immediate-release bioadhesive is orally administered, convenient to carry, convenient to store and convenient to use, and a patient using the positioning immediate-release bioadhesive does not need to go to a hospital, perform an operation or use endoscopy and further has no pain, thereby enhancing the compliance of a user and avoiding the complexity of the operation.

The invention discloses an essence formula with cantaloupe fragrance. According to mass parts, the formula comprises 10-25 parts of cantaloupe aldehyde, 5-10 parts of rose essential oil, 1-4 parts ofethyl vanillin, 2-5 parts of ethyl acetate, 1-3 parts of ethyl butyrate and 0.5-1.5 parts of butyl lactate. According to the formula, by adding the rose essential oil, mint essential oil and cinnamonoil, essence has slight fragrance suitable for being matched with the cantaloupe fragrance, can dispel coldness and rheumatism and has multiple treatment effects on toothaches and coughs; by adding the cinnamon oil, the essence further has the effects of dispelling rheumatism and warming and strengthening spleens and stomachs; by adding the mint essential oil which is fragrant and refreshing, thefragrance of the essence is enhanced; and mint is optimal essential oil for treating a cold, can suppress fevers and mucosal inflammations, promote sweating, clear lungs to wet throats, remove ozostomia, provide a cool feeling for analgesia and relieve headaches, migraine and toothaches and besides plays a good role in a respiratory system, a digestive system and an endocrine system.

The invention relates to application of Zizhu Darcy in inhibition of gastric mucosa inflammation caused by helicobacter pylori infection, and belongs to the technical field of biological medicine. Animal in-vivo experiments prove that the Zhuzudaxi can reverse gastric mucosal lesion caused by helicobacter pylori infection to a certain extent and relieve gastric mucosal inflammation caused by helicobacter pylori infection. Therefore, the Zhuzhu Darcy has important clinical application value in the aspect of inhibiting inflammation caused by helicobacter pylori infection.

The invention discloses a Tibetan medicine composition for treating chronic superficial gastritis, which consists of active components made of the following crude drugs in parts by weight: 50 parts of Tibetan woody fragrance, 200 parts of rhubarb, 100 parts of kaempferia, calcined Beihan Shuishi 250 parts, Myrobalan 150 parts. The active component can be the crushed fine powder of the crude drug; it is also possible to routinely extract and dry the Akiras sinensis, rhubarb, kaempferia, and chebula in the crude drug, then add calcined northern cold water stone, and pulverize Made into fine powder. The pharmacodynamics test on chronic superficial gastritis in rats shows that after using the Tibetan medicine composition of the present invention, body weight increases significantly; it can effectively inhibit gastric mucosal inflammation and reduce gastric mucosal pathological damage, promote gastric circulation blood flow, It reduces the content of serum GAS, inhibits the activation of G cells, reduces the secretion of gastric acid, and protects the injured part of the gastric mucosa. This prescription has a good effect on the treatment of chronic superficial gastritis.

The invention provides methods for the identification of patients capable of controlling HIV progression, as well as to the identification of an antagonist form of IP-10 associated to HIV progression control and the uses thereof for improving the immunological response of HIV patients.

The invention discloses a traditional Chinese medicine preparation for treating reflux esophagitis. The traditional Chinese medicine preparation is prepared from the following medicinal materials in parts by weight: 10 parts of tree peony root bark, 10 parts of cape jasmine, 10 parts of herb of resupinate woodbetony, 12 parts of white peony root, 6 parts of radix bupleuri, 10 parts of seed of squarrose agriophyllum, 10 parts of mirabilite, 3 parts of carbonized human hair, 15 parts of pennycress seed, 6 parts of tragacanth, 10 parts of skin on boiled milk, 10 parts of fleshy lysionotus, inula flower, 15 parts of halite, 15 parts of lalang grass rhizome and 10 parts of honeysuckle. Clinical experiments prove that the traditional Chinese medicine preparation for treating reflux esophagitis has excellent curative effect on the improvement of cardinal symptoms of the reflux esophagitis, the elimination of gastric juice reflux, the repair and protection of the esophagus mucosa, and the elimination of mucosal inflammation due to the appropriate selection of the medicinal materials and the proportions thereof, and as the medicine takes effect, the symptoms are lessened, and moreover, the traditional Chinese medicine preparation has good prevention effect on pathogenesis transmission and invasion into viscera and has a great value in clinical application.

The present invention pertains to specific clonidine and / or clonidine derivatives for use in the prevention and / or treatment of adverse side effects of alkylating agent chemotherapy, other than those resulting from mucosal inflammation. It also pertains to the use of this clonidine and / or clonidine derivative for the manufacture of a pharmaceutical composition intended to prevent and / or alleviate the adverse side effects of alkylating agent chemotherapy, other than those resulting from mucosal inflammation. This invention is further directed to a kit comprising: (a) a clonidine and / or clonidine derivative, and (b) at least one alkylating chemotherapeutic agent, as a combined preparation for simultaneous, separate or sequential use in the treatment of cancer.

Linolenic acid-metronidazole compound and its preparation method and application, adding linolenic acid, dichloromethane, dicyclohexylcarbodiimide condensing agent in a reaction vessel, after stirring at room temperature for 5 minutes, adding metronidazole, triethylamine ( As a base), 4-dimethylaminopyridine was used as a catalyst, and the reaction was carried out at room temperature overnight. Thin-layer chromatography (TLC) detected that the raw material of linolenic acid disappeared completely, and the system had a white precipitate, which was filtered through diatomaceous earth. The filtrate was spin-dried to obtain a metronidazole-linolenic acid esterified product by column chromatography. The invention successfully prepares the linolenic acid-metronidazole compound with a high yield of 48.7%, and the compound has a good inhibitory effect on Helicobacter pylori in vivo and in vitro, especially Helicobacter pylori resistant to metronidazole , Can promote the repair of gastric mucosal inflammation in mice; it is stable in an acidic environment, has low cytotoxicity, and has strong specificity; it is not easy to develop drug resistance, and can be used as the first choice for the treatment of Helicobacter pylori.